EGF and neoplasm: Owing to its function as a tumour suppressor, however, there is some evidence that PTEN has significant impact on the efficiency of targeted therapies by antagonising the activation of the PI3K–AKT pathway that is predominantly activated by EGF-/HER2-receptor tyrosine kinases in different tumour types.